Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma

J Natl Cancer Inst. 2004 Apr 21;96(8):636-7. doi: 10.1093/jnci/djh108.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / blood
  • Antineoplastic Agents, Hormonal / pharmacokinetics*
  • Chromatography, High Pressure Liquid
  • Drug Administration Schedule
  • Estrogen Receptor Modulators / administration & dosage*
  • Estrogen Receptor Modulators / adverse effects
  • Estrogen Receptor Modulators / blood
  • Estrogen Receptor Modulators / pharmacokinetics*
  • Feasibility Studies
  • Humans
  • Multiple Myeloma / drug therapy*
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • Tamoxifen / administration & dosage*
  • Tamoxifen / adverse effects
  • Tamoxifen / blood
  • Tamoxifen / pharmacokinetics*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Estrogen Receptor Modulators
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen